This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Roger C. Bone, MD

JAMA. 1996;276(7):565-566.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

FEW CRITICAL conditions in medicine are as paradoxical as the events occurring during sepsis. The response of the patient's body to an insult such as infection or severe injury may initially be appropriate, but such defenses can lose their usual balance and destroy the patient. If the defense forces could be down-regulated after they have responded to the initial insult but before they begin destroying the body itself, we could prevent sepsis from developing—or at least reduce the associated mortality.

Deceptively simple, a viable way to accomplish this downregulation has eluded intense clinical research scrutiny for more than 10 years. All the trials of new therapies for sepsis conducted to date have failed to show efficacy (Table). Conducted under the rigorous conditions of the double-blind, randomized, placebo-controlled trial, their uniformly negative results have provoked great disappointment.

I believe the trials have reached the correct conclusion. The problem has not been . . . [Full Text PDF of this Article]

Author Affiliations
From the Department of Medicine, Rush Medical College of Rush University, Chicago, III.

Footnotes
Reprints: Roger C. Bone, MD, Office of the Dean, Rush Medical College of Rush University, 600 S Paulina, Ste 202, Chicago, IL 60612.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?